Can Decaffeinated Coffee Increase Alertness Without the Vigilance Effects of Regular Coffee? A 59-Adult Crossover Study

Answer: Yes, in one controlled experiment decaffeinated coffee increased self-rated alertness compared with a coffee-flavored placebo, while the clearest improvements in objective attention favored regular coffee. Among 59 analyzed habitual caffeine consumers, regular coffee containing approximately 100 mg of caffeine improved digit-vigilance reaction time and rapid visual-information-processing speed compared with placebo, and digit-vigilance accuracy compared with decaffeinated coffee. Decaffeinated coffee contained approximately 5 mg of caffeine and produced higher alertness ratings than placebo, but the investigators did not demonstrate the same set of statistically significant objective vigilance improvements for decaffeinated coffee. These are group-level laboratory observations, not a validated prediction of how a particular person will drive, testify, make a decision, or respond to an emergency.

The original primary experiment is Haskell-Ramsay and colleagues, The Acute Effects of Caffeinated Black Coffee on Cognition and Mood in Healthy Young and Older Adults, Nutrients 2018;10:1386, doi:10.3390/nu10101386. Its especially important forensic feature is that researchers chemically assayed caffeine in saliva. They did not report caffeine concentrations in venous whole blood, separated serum or plasma. A saliva result, beverage caffeine dose, computerized response, and legal impairment conclusion are four different things.

What question did the trial actually test?

The trial did not simply ask whether consuming caffeine makes people feel more awake. It compared three beverages: regular brewed black coffee, decaffeinated brewed black coffee, and an engineered coffee-flavored placebo. That design matters because decaf is not the same intervention as plain water. It carries a small residual caffeine exposure and other coffee constituents, and it looks and tastes more like the experimental beverage than an inert laboratory solution. Without a true placebo, a study contrasting only regular versus decaf might incorrectly allocate all observed differences to the absence or presence of caffeine.

The investigators separately evaluated attention, memory, learning, a short driving simulation, and visual-analogue ratings of mental state. They also explored whether age and sex altered beverage effects. These were distinct outcome families; a positive finding in one cannot be automatically transferred to another. The best narrow conclusion concerns short-term self-reported alertness versus selected measured attention tasks under the study’s controlled conditions.

Who participated, and what does the sample size mean?

Seventy-two people completed the experimental visits, but the protocol-based analysis excluded 13: twelve had excessive predose salivary caffeine above the study’s 1 µg/mL screening criterion, and one consumed too little of the assigned drink. The analyzed sample was therefore 59 independent people: 29 adults aged 20–34 years and 30 aged 61–80 years. The young group contained 16 men and 13 women; the older group contained 14 men and 16 women. Each person experienced all three treatment conditions, separated by a minimum one-week interval. Three visits are repeated observations on the same person, not 177 independent participants.

Eligibility required habitual caffeine consumption equivalent to at least about 150 mg daily, and participants were generally healthy, nonsmoking English speakers. Older participants could use certain routine medications; young women could use contraception. Participants were not recruited as impaired drivers, shift workers in an operational trial, people with substance-use disorders, or patients evaluated for a clinical intoxication diagnosis. Thus, age-stratified results can describe this selected population without identifying a decision threshold for an unrelated forensic case.

How were the beverages administered?

Each test drink was 220 mL. The regular coffee supplied approximately 100 mg caffeine; the decaffeinated brew supplied approximately 5 mg; placebo was hot water with 2.5 g of coffee flavoring, mainly maltodextrin plus roast-flavor components. Investigators used standardized filtered brewing, opaque vessels and straws, and a serving temperature around 58°C. Treatment order was computerized and counterbalanced by sex and age category. The design was described as randomized and double-blind.

Participants were asked to avoid caffeine from noon on the preceding day, with abstention kept under 24 hours, and to standardize breakfast. That is important: some short-term test-day improvement in habitual users could reflect withdrawal relief rather than a universal gain above their ordinary functioning. The study did not directly test lifelong caffeine-naive people or compare their everyday baseline behavior with regular drinkers. Also, because beverage exposures contained multiple chemical constituents, this trial cannot by itself distinguish every molecular mechanism of alertness.

What physical specimen was actually analyzed?

Researchers collected saliva with commercial salivettes before cognitive testing and after the test drink and assessments. Samples were frozen, thawed, centrifuged and processed with an organic-solvent extraction. The extracted specimens were evaluated by high-performance liquid chromatography with ultraviolet detection at 280 nm. Standards for caffeine and paraxanthine were prepared across 0.05–5.00 µg/mL, with a quality-control preparation at 2.5 µg/mL. The article identifies benzotriazole as an internal standard. These are particulars of the study’s saliva-analysis method, not an assertion that it was validated for whole blood or every forensic reporting range.

The investigators reported a baseline salivary caffeine concentration of 0.17 µg/mL for the analyzed sample and a strong beverage-treatment effect on postdose salivary caffeine. Postdose saliva caffeine was greater after regular coffee than after both decaf and placebo, with the reported pairwise comparisons each p<0.0001. Figure 3 presents adjusted means and uncertainty bars; the paper does not provide an exact numeric postdose concentration for every arm in its main narrative. Accordingly, a value estimated by eye from the figure should not be marketed as a precise validated result.

Study design and analytical evidence

The source used an analysis of postdose outcomes adjusted for respective baseline scores and included beverage, age, sex and interactions. It followed reported significant findings with Bonferroni-adjusted comparisons. Those steps reduce some interpretive errors but cannot make a short experiment an individualized legal test. The original article also references supplementary tables containing broader numerical details; the main published paper’s statistical contrasts, not inferred values from graphs, support the comparisons summarized here.

What happened on the objective vigilance tasks?

Regular coffee performed best on selected attention endpoints. On the three-minute digit-vigilance task, participants monitored rapidly changing digits and responded to a match. The overall beverage effect on accuracy was F(2,101.1)=4.44, p=0.014. A direct post-hoc comparison favored regular over decaffeinated coffee, p=0.01. The corresponding digit-vigilance reaction-time treatment effect was F(2,71.3)=5.07, p=0.009, with regular coffee producing faster responses than placebo, p=0.009. These are two related but different metrics: accuracy and speed.

On rapid visual information processing (RVIP), a five-minute task requiring detection of sequences among quickly presented digits, the overall reaction-time effect was F(2,102.9)=3.77, p=0.026. Regular coffee was faster than placebo on the reported post-hoc comparison, p=0.02. Figure 4 displays all three beverage arms but does not establish a significant regular-versus-decaf difference on every plotted outcome. Nor does a plotted intermediate position for decaf prove a statistically reliable halfway benefit. The relevant question is which contrast was formally tested and significant, not whether one bar looks higher.

Could decaffeinated coffee improve perceived alertness?

Yes, a significant group difference was reported for the subjective alertness rating. Beverage treatment yielded F(2,106)=9.86, p<0.0001. Relative to placebo, regular coffee increased alertness ratings, p<0.0005, but decaffeinated coffee also increased alertness ratings, p=0.0048. This specific finding is why it is scientifically unsafe to assume that decaf always functions as a behaviorally inactive placebo when a study’s endpoint is how alert a participant says they feel.

That finding does not prove decaf has the same effect as 100 mg caffeine or that its residual 5 mg caffeine was solely responsible. The two types of brewed coffee differ in several constituents and in the processes used to remove caffeine. The trial included neither a pure isolated-caffeine beverage matched for coffee flavor nor direct quantitation of phenolic compounds after consumption. A placebo expectation, withdrawal relief, non-caffeine constituents or interacting factors are plausible hypotheses; the original randomized comparisons do not establish which one caused the difference.

What did the trial find about tiredness, headache and mood?

Regular coffee generated lower tiredness ratings than decaf (p=0.003) and placebo (p<0.0001). It was also associated with lower headache ratings than decaf (p=0.0049) and placebo (p=0.015). Overall mood ratings were higher for regular coffee than placebo, p=0.004, and mental-fatigue ratings were lower, p=0.01. These scores were obtained on visual-analogue scales that represent subjective state, not measured concentration in a biological matrix or a valid adjudication of how well a witness perceived an event.

A useful distinction is that being less tired and being objectively more accurate are not interchangeable results. A person may report alertness without a matching change in test accuracy, or may complete a short task faster without improving detection of rare hazards. In real cases, subjective ratings need to be interpreted together with the task, time, dose, habitual exposure, sleep, illness, medications and any directly obtained performance evidence. This paper does not furnish a universal conversion between subjective scales and a safety-critical performance score.

Which findings were not significant?

Several reported interactions did not yield significant follow-up comparisons. For RVIP false alarms, the treatment-by-sex interaction had p=0.013, but post-hoc pairwise comparisons identified no significant effects. For delayed computerized location-learning recall, the treatment-by-sex interaction was p=0.035, again without significant pairwise comparisons. It would be incorrect to convert those omnibus interactions into a confident statement that a specific beverage improved a particular subgroup on those endpoints.

The original narrative did not identify a reliable beverage effect for every working-memory, episodic-memory, simulated-driving or location-learning measure. An outcome not established as a significant treatment contrast in the report must not be declared proof of equivalence, proof of no biologic effect, or a new unreported p-value. In particular, the researchers included a short driving simulation in their battery; that does not amount to a controlled on-road impairment study or a conclusion that any beverage prevented a real collision.

Which numerical comparisons can be supported directly?

These values are reported hypothesis-test results, not a concentration-based diagnostic rule. The authors used multiple cognitive and mood endpoints and explored age-sex interactions. Even within a randomized study, the more endpoints tested, the more care is required with isolated nominal p-values and apparent subgroup signals. The figures help explain pattern and magnitude but do not supply a missing individual effect size, diagnostic sensitivity, or forensic classification threshold.

Did younger and older participants react differently?

Both age groups contributed to the experimental comparisons, but the authors did not report reliable age-by-treatment effects on the central cognitive measures. They observed differences in baseline memory performance by age; those ordinary age-related differences are not evidence that coffee reversed cognitive ageing. The participants over 60 were comparatively healthy and educated, and the study did not include adults above age 80 in sufficient numbers to answer questions about frailty or dementia. An average result for a selected older adult group cannot be generalized to an older patient with neurologic disease or polypharmacy.

One self-report outcome did show a three-way treatment-by-age-by-sex interaction: jitteriness, F(3,76.2)=3.01, p=0.035. Follow-up tests showed higher jitteriness following regular coffee compared with placebo among young women (p=0.046), and compared with decaf among older men (p=0.045). This does not establish a fixed susceptibility for all women or men. The investigators did not control menstrual-cycle phase, and genetic differences in caffeine metabolism were not directly genotyped. Those limitations matter before using subgroup observations to claim what happened to an individual at a particular time.

Why does the distinction between saliva and blood matter?

Saliva was the actual analytical specimen. It underwent collection, storage, extraction and HPLC-UV measurement. A concentration in this matrix is not automatically the concentration that would appear in directly collected venous whole blood, separated serum or plasma at the same time. Salivary caffeine can help document recent absorbed exposure under the research method, but a conversion to an individual’s blood concentration would require separately validated matrix relationships, sampling timing and other biological information. Biological matrices in forensic toxicology explains why the tested compartment must remain attached to every reported number.

Likewise, the nominal 100 mg beverage dose is an administered exposure; it is not a measurement of whole-blood caffeine. A response-time difference measured by software is a behavioral endpoint. A mood score is a subjective report. None can substitute for the others. If someone seeks to reconstruct a legal toxicology event, it is necessary to identify the actual laboratory instrument, chemical specificity, controls and validated biological reporting units, and distinguish exposure evidence from any allegation about contemporaneous performance.

Does HPLC analysis prove the mechanism of decaf’s effect?

No. HPLC-UV measured caffeine and enabled researchers to compare salivary exposure across drinks. It did not quantify chlorogenic acids, their metabolites or all the hundreds of other coffee constituents potentially relevant to responses. The source discusses possible non-caffeine contributions but did not experimentally isolate and administer these candidate compounds in separate arms. It also did not establish a dose-response curve for pure caffeine across the 5-to-100-mg range. Consequently, the observed decaf alertness result is evidence of a beverage-condition difference, not proof of one specific receptor, metabolite or signaling pathway.

Method specificity remains central: retention behavior and ultraviolet detection on a defined chromatographic system address the research analytes within that method; they do not automatically establish a legally validated, confirmatory blood drug panel. Readers assessing a real laboratory report can use the principles in confirmatory drug testing to separate validated chemical identification from interpretations of concentration, performance and source.

Could expectancy and incomplete blinding explain some results?

After the final visit, 71% of participants correctly identified which beverage they had just consumed. Recognition was particularly high for regular coffee, reported at 81%; 72% correctly identified decaf and 58% placebo. This assessment was made at the last visit, not independently after each individual administration, so it cannot precisely determine blinding quality during all three earlier sessions. Nonetheless, the figures underscore the problem of keeping flavorful psychoactive beverages genuinely indistinguishable even with opaque cups, standardized serving temperature and randomized assignment.

Expectancy can influence self-rated alertness, and a habitual drinker’s mild withdrawal symptoms may change with access to their usual beverage. At the same time, a randomized crossover design helps control many stable differences between participants. The appropriate conclusion is neither that expectancy explains everything nor that blinding was perfect. The actual trial demonstrates beverage effects under a combination of sensory, chemical and expectation conditions; separating those contributors requires a stronger factorial design.

How far can the measured effects be generalized?

Only a brief period was tested after a standardized morning drink, with most cognitive assessments beginning approximately 30 minutes afterward. The work did not establish effects over an eight-hour shift, through a night without sleep, under strenuous heat or physical exertion, or during emergency aviation decisions. The simulated-driving task was short and did not produce a validated individual crash-risk classification. The authors did not observe real collisions, emergency mistakes, eyewitness identification errors, workplace injuries or the competence of any specific driver. Even a statistically significant average shortening of a button-press latency would not prove reliable avoidance of an unpredictable hazard.

All analyzed participants were habitual consumers. The trial excluded twelve apparent nonadherent people on the basis of elevated baseline saliva caffeine. That exclusion may improve protocol compliance but narrows generalizability and makes predose screening part of the reported study denominator. Women of reproductive age were not stratified by verified menstrual-cycle phase. Also, a beverage’s constituents and their absorption may change with roasting, preparation, diet and individual metabolism. The correct scientific answer stays within these observations and is not a legal opinion about an untested person.

What would a stronger forensic study need?

A follow-up experiment intended for use in drug-effect reconstruction would separately measure time-stamped venous whole blood and plasma or serum, alongside saliva, with matrix-appropriate assay validation, calibration, quality controls and repeat sampling. It would include caffeine-only, coffee-matched decaf, coffee-matched regular and true placebo arms, preferably with matched odor and taste and systematic assessment of guessing. A wider testing window would be necessary to evaluate the effects of other coffee constituents whose absorption and metabolism may lag behind caffeine.

The performance component should preselect a limited set of endpoints tied to the target legal or occupational question, report multiplicity-adjusted comparisons and test independent replication. For driving, monitored on-road or ecologically validated driving outcomes would be more informative than assuming that digit vigilance represents the ability to avoid a collision. For drug concentration interpretation, therapeutic drug monitoring illustrates why a timed result needs dose history and the correct specimen before any pharmacokinetic conclusion is attempted.

Practical interpretation for forensic science

Three claims can be defended from this original primary experiment. First, regular brewed coffee delivering about 100 mg caffeine produced statistically supported group improvements in selected attention speed and accuracy endpoints. Second, decaffeinated brewed coffee containing about 5 mg caffeine produced a significant improvement in self-reported alertness versus a coffee-flavored placebo, even though equivalent objective attention gains were not established by the reported contrasts. Third, measured salivary caffeine confirmed different exposure patterns across beverage assignments; the experiment did not quantify caffeine in human venous whole blood or validate an individual impairment classifier.

The result is useful chiefly as a warning against substituting one kind of evidence for another. Decaf may not be an inert comparator for subjective mood research, but subjective alertness is not driving fitness; a laboratory button press is not the real-world incident; and a concentration in saliva is not a blood result. Preserve those distinctions when reviewing claims about stimulant effects, behavior, toxicologic specimens and causation.

Frequently asked questions

1. Does this experiment prove that decaffeinated coffee has no caffeine?

No. The decaffeinated brew was described as containing approximately 5 mg caffeine per 220-mL serving. Its salivary result therefore cannot be treated as the exposure of a completely caffeine-free control. The researchers also did not isolate every other constituent in the decaffeinated beverage.

2. How many independent people were actually analyzed?

Fifty-nine: 29 young adults and 30 older adults. Seventy-two people completed the three visits; twelve were excluded for elevated baseline saliva caffeine and one for insufficient drink consumption. The three sessions and multiple computerized tasks are repeated measurements, not more independent participants.

3. Did decaffeinated coffee improve objective attention as much as regular coffee?

The paper does not support that equivalence claim. Decaf increased subjective alertness compared with placebo. Regular coffee, however, showed specific statistically significant digit-vigilance and RVIP improvements and outperformed decaf on digit-vigilance accuracy. Failure to report a significant decaf improvement is not formal proof of zero effect.

4. Was the caffeine concentration measured in whole blood?

No. Investigators chemically analyzed processed saliva by HPLC-UV, reporting caffeine in µg/mL. They did not directly assay legal venous whole blood, separated serum or plasma for caffeine in this experiment. Any cross-matrix relationship would need separate evidence and validation.

5. What does a faster computerized reaction time say about DUI impairment?

It describes performance on that controlled computerized task. It does not establish a validated person’s driving-impairment threshold, crash avoidance, ability to perceive an unexpected event, or causation in a particular case. Real-world impairment assessment requires separate evidence and case-specific context.

6. Did older people gain more than younger participants?

The authors did not establish a reproducible age-by-treatment advantage on the central cognitive outcomes. The main age-sex-treatment signal concerned self-reported jitteriness, with selected comparisons in young women and older men. Small subgroup sizes and uncontrolled hormonal factors limit individualized conclusions.

7. What is the single most defensible conclusion for a toxicology report?

In 59 selected habitual caffeine consumers, one 100-mg caffeine brewed-coffee condition improved certain short-term attention measures, while roughly 5-mg caffeine decaf improved subjective alertness compared with flavored placebo. These effects were associated with salivary caffeine measurements and do not establish a whole-blood concentration or any individual’s legal impairment.

Primary study: Haskell-Ramsay CF, Jackson PA, Forster JS, Dodd FL, Bowerbank SL, Kennedy DO. The Acute Effects of Caffeinated Black Coffee on Cognition and Mood in Healthy Young and Older Adults. Nutrients. 2018;10(10):1386. https://doi.org/10.3390/nu10101386.